메뉴 건너뛰기
Clinical Cancer Research
Volumn 23, Issue 20, 2017, Pages 6376-6377
Genomics of immunotherapy-associated hyperprogressors - Response
Author keywords

[No Author keywords available]
Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; IMMUNOLOGIC FACTOR;
EID: 85031497018     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-1990     Document Type: Letter
Times cited : (9)
References (3)
  • 1
    • 85026810566 scopus 로고    scopus 로고
    • Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate
    • Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017;23:4242–50.
    • (2017) Clin Cancer Res , vol.23 , pp. 4242-4250
    • Kato, S.1    Goodman, A.2    Walavalkar, V.3    Barkauskas, D.A.4    Sharabi, A.5    Kurzrock, R.6
  • 2
    • 85018847861 scopus 로고    scopus 로고
    • Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1
    • Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23: 1920–8.
    • (2017) Clin Cancer Res , vol.23 , pp. 1920-1928
    • Champiat, S.1    Dercle, L.2    Ammari, S.3    Massard, C.4    Hollebecque, A.5    Postel-Vinay, S.6
  • 3
    • 84873055344 scopus 로고    scopus 로고
    • MDM2, MDMX and p53 in oncogenesis and cancer therapy
    • Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83–96.
    • (2013) Nat Rev Cancer , vol.13 , pp. 83-96
    • Wade, M.1    Li, Y.C.2    Wahl, G.M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.